Table 11.
Distribution of all histologically-confirmed brain and other central nervous system tumors by WHO grade, treatment information completeness, and major histology grouping, CBTRUS Statistical Report: U.S. Cancer Statistics – NPCR and SEER, 2012–2016
| Histology | Number of Newly Diagnosed Tumors | Histologically Confirmed (%) | WHO Grade Completeness (%) | Assigned WHO Grade | Radiation Information Completenessb (%) | Surgical Extent of Resection Information Completenessc (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Completea | Incomplete | Not Applicable | WHO Grade I | WHO Grade II | WHO Grade III |
WHO Grade IV | |||||
| Tumors of Neuroepithelial Tissue | 112,280 | 89.2% | 85.6% | 12.9% | 1.5% | 10.6% | 14.0% | 13.3% | 62.0% | 54.9% | 98.0% |
| Pilocytic Astrocytoma | 5,166 | 90.8% | 87.4% | 12.1% | 0.5% | 92.9% | 5.9% | 0.8% | 0.4% | 6.0% | 99.1% |
| Diffuse Astrocytoma | 7,500 | 92.4% | 85.6% | 14.3% | 0.1% | 3.4% | 64.1% | 19.5% | 13.0% | 49.6% | 97.7% |
| Anaplastic Astrocytoma | 7,015 | 99.2% | 94.8% | 5.1% | 0.1% | 0.1% | 1.3% | 90.2% | 8.5% | 77.3% | 99.2% |
| Unique Astrocytoma Variants | 1,161 | 75.5% | 75.8% | 23.9% | 0.3% | 21.4% | 55.3% | 18.1% | 5.3% | 20.9% | 98.2% |
| Malignant | 785 | 87.1% | 78.4% | 21.3% | 0.3% | 2.6% | 68.5% | 22.4% | 6.5% | 30.2% | 97.9% |
| Non-Malignant | 376 | 51.1% | 66.7% | 32.8% | 0.5% | 100.0% | 0.0% | 0.0% | 0.0% | 1.7% | 98.8% |
| Glioblastoma | 59,164 | 93.2% | 88.7% | 11.2% | 0.0% | 0.2% | 0.2% | 0.8% | 98.9% | 69.4% | 97.7% |
| Oligodendroglioma | 3,668 | 96.9% | 92.9% | 7.1% | 0.0% | 1.5% | 87.9% | 5.8% | 4.8% | 32.7% | 98.4% |
| Anaplastic Oligodendroglioma | 1,808 | 98.9% | 95.1% | 4.9% | 0.0% | 0.1% | 2.9% | 88.7% | 8.3% | 69.3% | 98.5% |
| Oligoastrocytic Tumors | 2,103 | 99.2% | 95.0% | 5.0% | 0.0% | 0.8% | 51.1% | 40.1% | 8.0% | 56.5% | 99.3% |
| Ependymal Tumors | 6,877 | 89.2% | 86.1% | 13.9% | 0.0% | 36.2% | 48.9% | 14.1% | 0.8% | 26.2% | 98.5% |
| Malignant | 4,005 | 93.6% | 89.0% | 11.0% | 0.1% | 2.5% | 74.2% | 22.1% | 1.1% | 38.2% | 98.6% |
| Non-Malignant | 2,872 | 82.9% | 81.5% | 18.5% | 0.0% | 94.1% | 5.5% | 0.3% | 0.1% | 9.4% | 98.4% |
| Glioma Malignant, NOS | 7,751 | 33.8% | 46.5% | 52.4% | 1.1% | 18.2% | 28.0% | 25.3% | 28.5% | 27.5% | 97.5% |
| Choroid Plexus Tumors | 817 | 88.1% | 76.1% | 23.9% | 0.0% | 63.9% | 18.8% | 16.4% | 0.9% | 4.5% | 98.2% |
| Malignant | 131 | 96.9% | 82.7% | 17.3% | 0.0% | 5.7% | 3.8% | 85.7% | 4.8% | 14.9% | 100.0% |
| Non-Malignant | 686 | 86.4% | 74.7% | 25.3% | 0.0% | 77.7% | 22.3% | 0.0% | 0.0% | 2.5% | 98.0% |
| Other Neuroepithelial Tumors | 109 | 93.6% | 48.0% | 51.0% | 1.0% | 8.2% | 53.1% | 26.5% | 12.2% | 37.6% | 100.0% |
| Malignant | 72 | 98.6% | 40.8% | 57.7% | 1.4% | 10.3% | 24.1% | 44.8% | 20.7% | 50.8% | 100.0% |
| Non-Malignant | 37 | 83.8% | 64.5% | 35.5% | 0.0% | 5.0% | 95.0% | 0.0% | 0.0% | 13.9% | 100.0% |
| Neuronal and Mixed Neuronal Glial Tumors | 4,852 | 92.7% | 62.7% | 20.0% | 17.3% | 80.5% | 15.1% | 3.6% | 0.7% | 15.9% | 98.6% |
| Malignant | 976 | 98.8% | 16.3% | 5.0% | 78.7% | 25.5% | 8.9% | 56.7% | 8.9% | 62.0% | 98.1% |
| Non-Malignant | 3,876 | 91.1% | 75.4% | 24.0% | 0.5% | 83.7% | 15.5% | 0.5% | 0.3% | 4.4% | 98.7% |
| Tumors of the Pineal Region | 796 | 76.0% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 40.4% | 97.7% |
| Malignant | 445 | 95.7% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 65.2% | 98.6% |
| Non-Malignant | 351 | 51.0% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 9.3% | 97.0% |
| Embryonal Tumors | 3,493 | 98.0% | 75.2% | 24.1% | 0.7% | 1.4% | 0.2% | 1.4% | 97.0% | 61.9% | 97.6% |
| Tumors of Cranial and Spinal Nerves | 35,053 | 50.6% | 34.1% | 65.9% | 0.0% | 99.0% | 0.5% | 0.2% | 0.2% | 18.2% | 98.2% |
| Nerve Sheath Tumors | 35,017 | 50.6% | 34.1% | 65.9% | 0.0% | 99.0% | 0.5% | 0.2% | 0.2% | 18.2% | 98.2% |
| Malignant | 231 | 80.5% | 21.5% | 78.5% | 0.0% | 47.5% | 17.5% | 20.0% | 15.0% | 38.6% | 83.2% |
| Non-Malignant | 34,786 | 50.4% | 34.2% | 65.8% | 0.0% | 99.4% | 0.4% | 0.1% | 0.1% | 18.1% | 98.3% |
| Other Tumors of Cranial and Spinal Nerves | 36 | 41.7% | 26.7% | 73.3% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 2.8% | 100.0% |
| Tumors of Meninges | 157,310 | 41.3% | 77.7% | 22.2% | 0.1% | 80.3% | 17.5% | 2.1% | 0.1% | 7.5% | 97.7% |
| Meningioma | 152,756 | 40.0% | 79.3% | 20.7% | 0.0% | 80.5% | 17.7% | 1.7% | 0.1% | 7.2% | 97.7% |
| Malignant | 1,774 | 79.0% | 84.9% | 15.1% | 0.0% | 21.9% | 17.3% | 59.6% | 1.2% | 38.4% | 85.3% |
| Non-Malignant | 150,982 | 39.5% | 79.1% | 20.8% | 0.0% | 82.0% | 17.7% | 0.2% | 0.1% | 6.9% | 97.8% |
| Mesenchymal Tumors | 1,433 | 72.8% | 52.3% | 47.2% | 0.5% | 8.1% | 47.4% | 39.9% | 4.6% | 30.6% | 98.1% |
| Primary Melanocytic Lesions | 109 | 91.7% | 13.0% | 84.0% | 3.0% | 53.8% | 30.8% | 7.7% | 7.7% | 43.6% | 89.7% |
| Other Neoplasms Related to the Meninges | 3,012 | 91.5% | 55.2% | 43.4% | 1.3% | 99.2% | 0.5% | 0.1% | 0.2% | 7.3% | 98.4% |
| Lymphoma and Hematopoietic Neoplasms | 7,914 | 94.6% | 5.1% | 94.0% | 0.8% | 100.0% | 0.0% | 0.0% | 0.0% | 22.0% | 99.2% |
| Lymphoma | 7,680 | 94.8% | 5.4% | 94.2% | 0.4% | 100.0% | 0.0% | 0.0% | 0.0% | 21.7% | 99.1% |
| Other Hematopoietic Neoplasms | 234 | 88.5% | 0.0% | 88.8% | 11.2% | -- | -- | -- | -- | 31.7% | 99.2% |
| Germ Cell Tumors and Cysts | 1,543 | 81.1% | 3.0% | 55.3% | 41.8% | 24.3% | 5.4% | 5.4% | 64.9% | 46.4% | 98.5% |
| Germ cell tumors, cysts, and heterotopias | 1,543 | 81.1% | 3.0% | 55.3% | 41.8% | 24.3% | 5.4% | 5.4% | 64.9% | 46.4% | 98.5% |
| Malignant | 1,037 | 88.4% | 3.3% | 43.4% | 53.3% | 6.7% | 6.7% | 6.7% | 80.0% | 68.0% | 98.7% |
| Non-Malignant | 506 | 66.2% | 2.1% | 87.8% | 10.1% | 100.0% | 0.0% | 0.0% | 0.0% | 2.5% | 97.9% |
| Tumors of Sellar Region | 71,084 | 48.3% | 0.4% | 0.6% | 99.0% | 100.0% | 0.0% | 0.0% | 0.0% | 3.2% | 97.8% |
| Tumors of the Pituitary | 68,020 | 46.7% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 2.3% | 97.8% |
| Malignant | 157 | 66.9% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 17.4% | 87.0% |
| Non-Malignant | 67,863 | 46.6% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 2.3% | 97.8% |
| Craniopharyngioma | 3,064 | 83.5% | 5.7% | 7.5% | 86.7% | 100.0% | 0.0% | 0.0% | 0.0% | 22.0% | 97.8% |
| Unclassified Tumors | 20,556 | 17.5% | 4.4% | 87.5% | 8.1% | 64.2% | 8.2% | 8.2% | 19.5% | 4.0% | 70.2% |
| Hemangioma | 5,982 | 29.3% | 2.3% | 97.2% | 0.5% | 87.8% | 7.3% | 2.4% | 2.4% | 2.1% | 97.6% |
| Neoplasm Unspecified | 14,418 | 12.3% | 6.1% | 78.7% | 15.3% | 57.4% | 9.3% | 9.3% | 24.1% | 5.1% | 60.3% |
| Malignant | 6,634 | 8.7% | 7.7% | 85.7% | 6.6% | 13.6% | 11.4% | 20.5% | 54.5% | 9.9% | 42.7% |
| Non-Malignant | 7,784 | 15.4% | 5.3% | 75.3% | 19.4% | 87.5% | 7.8% | 1.6% | 3.1% | 2.7% | 75.8% |
| All Other | 156 | 38.5% | 16.7% | 66.7% | 16.7% | 40.0% | 0.0% | 20.0% | 40.0% | 12.7% | 89.6% |
| TOTAL | 405,740 | 56.5% | 62.9% | 21.1% | 16.0% | 39.3% | 14.7% | 8.8% | 37.3% | 21.3% | 95.9% |
| Malignant | 122,569 | 85.3% | 80.5% | 17.5% | 2.0% | 6.2% | 14.2% | 15.0% | 64.7% | 54.8% | 92.3% |
| Non-Malignant | 283,171 | 44.1% | 48.4% | 24.0% | 27.5% | 84.3% | 15.3% | 0.3% | 0.1% | 7.1% | 97.1% |
a. Completeness is defined as having an assigned code that corresponds with a WHO grade as defined by the American Joint Commission on Cancer’s Collaborative Staging schema.
b. Radiation is defined using a recoded variable based on NAACCR Item #1360 (http://datadictionary.naaccr.org/default.aspx?c=10#136). Completeness is defined as having a value other than ‘none’ or ‘unknown.’
c. Surgery is defined using a recoded variable based on NAACCR Item #1290 (http://datadictionary.naaccr.org/default.aspx?c=10#1290). Please see the SEER site-specific surgery codes for more information on coding for this variable (https://seer.cancer.gov/archive/tools/SEER2003.surg.prim.site.codes.pdf). Completeness is defined as having a value other than ‘unknown.’
- Percentages are not presented when category is not applicable.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; CNS, central nervous system; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; WHO, World Health Organization